Efficacy and safety of biologics in erythrodermic psoriasis: a multicentre, retrospective study
- 13 March 2012
- journal article
- research article
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 167 (2), 417-423
- https://doi.org/10.1111/j.1365-2133.2012.10940.x
Abstract
Background Even though efficacy of biologics has been extensively studied in psoriasis vulgaris, studies in erythrodermic psoriasis, the most severe form of the disease, have been scarcely reported. Objectives To address the efficacy and safety of biologics in patients with erythrodermic psoriasis. Methods A multicentre national retrospective study was performed using the French Psoriasis Group network. Patients showing psoriasis involving at least 90% of body surface area (BSA), and in whom severity of the disease had been evaluated before and after 3 and/or 6 months of treatment with biologics, were enrolled in the study. Results were expressed using intention‐to‐treat analysis. Results We included 28 patients, representing 42 flares of erythrodermic psoriasis treated with infliximab (n = 24), adalimumab (n = 7), etanercept (n = 6), ustekinumab (n = 3) or efalizumab (n = 2). A 75% improvement of BSA or Psoriais Area and Severity Index 12–14 weeks after treatment onset was reached in 48% of flares treated with infliximab, in 50% of those treated with adalimumab and in 40% of those treated with etanercept. Twelve serious adverse events, consisting of bacterial infection in seven of them, were observed. Biological treatment was discontinued for safety concern in 19% of cases. A given biologic was administered for up to 48 weeks in 34% of flares. Conclusions Biologics show overall good short‐term efficacy, but treatment switch due to lack of efficacy or side‐effects is frequently observed on a longer term, with only one‐third of patients still receiving the same drug after 1 year. The most significant safety concern consists of severe infections.Keywords
This publication has 30 references indexed in Scilit:
- On the development of the European S3 guidelines on the systemic treatment of psoriasis vulgaris: structure and challengesJournal of the European Academy of Dermatology and Venereology, 2010
- Benefit-risk assessment of tumour necrosis factor antagonists in the treatment of psoriasisBritish Journal of Dermatology, 2010
- Comparison of Ustekinumab and Etanercept for Moderate-to-Severe PsoriasisNew England Journal of Medicine, 2010
- Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR)Annals Of The Rheumatic Diseases, 2009
- British Association of Dermatologists’ guidelines for biologic interventions for psoriasis 2009British Journal of Dermatology, 2009
- Risk of tuberculosis is higher with anti–tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three‐year prospective french research axed on tolerance of biotherapies registryArthritis & Rheumatism, 2009
- Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)The Lancet, 2008
- Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trialJournal of the American Academy of Dermatology, 2007
- A follow-up study in 28 patients treated with infliximab for severe recalcitrant psoriasis: evidence for efficacy and high incidence of biological autoimmunityBritish Journal of Dermatology, 2006
- Infectious complications of erythrodermic psoriasisJournal of the American Academy of Dermatology, 1996